NCT06708130 Allogeneic Hematopoietic Stem Cell Transplantation Cohort Study
| NCT ID | NCT06708130 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Ruijin Hospital |
| Condition | Allogeneic Hematopoietic Stem Cell Transplantation |
| Study Type | OBSERVATIONAL |
| Enrollment | 3,000 participants |
| Start Date | 2021-05-01 |
| Primary Completion | 2031-12-31 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 3,000 participants in total. It began in 2021-05-01 with a primary completion date of 2031-12-31.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Clinical observational studies using epidemiologic theories and methods. Through the collection of various clinically relevant data, specific outcomes are evaluated in hematologic transplant patients, providing high quality real-world data for clinical practice, informing public health decision-making, and reducing the burden of disease
Eligibility Criteria
Inclusion Criteria: 1. At least one visit to a stem cell transplant center beginning January 1, 2021 2. Proposed to undergo or have undergone hematopoietic stem cell transplantation Exclusion Criteria: 1. Long-term follow-up information for patients not available for any reason (e.g., unavailable or with serious concomitant disease) according to investigator opinion 2. Due to alcohol and drug addiction thus affecting their ability to follow the requirements of the study 3. Presence of conditions that could jeopardize patient safety or affect their adherence to the protocol, according to the investigator's opinion
Contact & Investigator
Frequently Asked Questions
Who can join the NCT06708130 clinical trial?
This trial is open to participants of all sexes, studying Allogeneic Hematopoietic Stem Cell Transplantation. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06708130 currently recruiting?
Yes, NCT06708130 is actively recruiting participants. Contact the research team at hu_xiaoxia@126.com for enrollment information.
Where is the NCT06708130 trial being conducted?
This trial is being conducted at Shanghai, China, Shanghai, China, Shanghai, China.
Who is sponsoring the NCT06708130 clinical trial?
NCT06708130 is sponsored by Ruijin Hospital. The trial plans to enroll 3,000 participants.